back
SEDI Insider filing browser
| Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
|---|---|---|---|---|---|---|
| Filed 2020-05-08 11:50 Tx date 2020-05-06 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
STILLER, CALVIN R.
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$13,737 vol $4.87 each |
$509,257 | |
| Filed 2020-01-02 16:46 Tx date 2019-12-31 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
STILLER, CALVIN R.
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$12,570 vol $1.16 each |
$495,520 | |
| Filed 2019-11-11 14:59 Tx date 2019-11-07 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
STILLER, CALVIN R.
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$348,333 vol $0.36 each |
$482,950 | |
| Filed 2019-10-02 15:10 Tx date 2019-09-30 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
STILLER, CALVIN R.
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$33,273 vol $0.4467 each |
$134,617 | |
| Filed 2019-07-03 13:57 Tx date 2019-06-30 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
STILLER, CALVIN R.
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$32,161 vol $0.4358 each |
$101,344 | |
| Filed 2019-04-05 09:58 Tx date 2019-03-31 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
STILLER, CALVIN R.
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$24,676 vol $0.92 each |
$69,183 | |
| Filed 2018-11-09 Tx date 2018-11-08 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
STILLER, CALVIN R.
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$29,181 vol $4.26 each |
$44,507 | |
| Filed 2017-11-14 Tx date 2017-11-09 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
STILLER, CALVIN R.
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$7,390 vol $12.18 each |
$15,326 | |
| Filed 2016-11-15 Tx date 2016-11-09 |
$TR
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
STILLER, CALVIN R.
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$7,936 vol $11.34 each |
$7,936 | |
| Filed 2016-11-15 Tx date 2016-11-09 |
$TR
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
STILLER, CALVIN R.
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$90,003
+7,936 vol $11.34 each |
||
| Filed 2016-11-15 Tx date 2011-07-18 |
$TR
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
STILLER, CALVIN R.
4 - Director of Issuer
Direct Ownership
|
Deferred share units
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2016-11-15 Tx date 2016-11-09 |
$TR
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
STILLER, CALVIN R.
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$90,003
+7,936 vol $11.34 each |
||
| Filed 2016-11-14 Tx date 2016-11-09 |
$TR
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
STILLER, CALVIN R.
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$90,003
+7,936 vol $11.34 each |
16,567 | |
| Filed 2016-05-10 Tx date 2016-05-09 |
$
Mercal Capital Corp. |
STILLER, CALVIN R.
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$11,000
+110,000 vol $0.10 each |
110,000 | |
| Filed 2016-05-10 Tx date 2016-04-04 |
$
Mercal Capital Corp. |
STILLER, CALVIN R.
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2016-04-12 Tx date 2016-04-04 |
$
Mercal Capital Corp. |
STILLER, CALVIN R.
4 - Director of Issuer
Holder: Stilco Corporation (Control or Direction)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
500,000 | ||
| Filed 2016-03-22 Tx date 2016-03-22 |
$TR
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
STILLER, CALVIN R.
4 - Director of Issuer
Holder: Stilco Corporation (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$100,026
+9,000 vol $11.11 each |
30,667 | |
| Filed 2015-12-23 Tx date 2015-12-21 |
$PSC
Percy Street Capital Corporation |
STILLER, CALVIN R.
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$15,857
+158,571 vol $0.10 each |
158,571 | |
| Filed 2015-12-23 Tx date 2015-12-01 |
$PSC
Percy Street Capital Corporation |
STILLER, CALVIN R.
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2015-12-15 Tx date 2015-12-09 |
$BVC
Magor Corporation (formerly Biovest Corp. I) |
STILLER, CALVIN R.
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
38 - Redemption, retraction, cancellation, repurchase
|
$-2,750
-55,000 vol $0.05 each |
0 |